What is NextCure?
NextCure operates at the intersection of biotechnology and immunology, focusing on the discovery and development of novel, first-in-class immunomedicines. The company's core mission is to transform the treatment paradigm for cancer and various immune-related conditions by identifying and validating unique biological targets. By maintaining a robust clinical-stage portfolio, NextCure distinguishes itself as a high-potential player in the biopharmaceutical sector, utilizing advanced scientific methodologies to translate laboratory breakthroughs into viable clinical solutions. Its strategic positioning is bolstered by a history of high-profile backing from both institutional venture capital firms and industry-leading pharmaceutical partners, providing the necessary infrastructure to sustain long-term innovation cycles.
How much funding has NextCure raised?
NextCure has raised a total of $324.8M across 4 funding rounds:
Series A
$67M
Stock Offering
$86.3M
Stock Offering
$150M
Other Financing Round
$21.5M
Series A (2016): $67M with participation from Canaan Partners, OrbiMed, Pfizer Inc., Sofinnova Ventures, Alexandria Venture Investments, and Lilly Asia Ventures
Stock Issuance/Offering (2019): $86.3M, investors not publicly disclosed
Stock Issuance/Offering (2019): $150M, investors not publicly disclosed
Other Financing Round (2025): $21.5M featuring Squadron Capital Management, Ikarian Capital, and Exome Asset Management
Key Investors in NextCure
Canaan Partners
Canaan is an early-stage venture capital firm that invests in technology and healthcare companies, backing founders from seed through growth stages in areas such as enterprise software, fintech, consumer, biopharma, and digital health.
OrbiMed
OrbiMed Advisors LLC operates as a specialized investment firm focused on the healthcare sector, with deep expertise spanning multiple therapeutic and commercial domains, including biopharmaceuticals and medical devices.
Pfizer Inc.
Pfizer Inc. is a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering innovative medicines and vaccines that improve health outcomes and enhance quality of life.
What's next for NextCure?
With the successful closure of its most recent financing round, NextCure is well-positioned to accelerate its clinical development programs and expand its therapeutic reach. The strategic deployment of this capital will likely focus on advancing lead candidates through critical trial phases, enhancing internal research infrastructure, and potentially exploring new collaborative opportunities to broaden its intellectual property portfolio. As the company transitions into more advanced stages of clinical validation, the focus will shift toward demonstrating efficacy and safety profiles that can support future regulatory filings and commercialization strategies. The ongoing support from specialized healthcare investors suggests a long-term commitment to the company's vision of delivering transformative medical outcomes in the oncology space.
See full NextCure company page
